SCHEMBL5849648

SCHEMBL5849648

CCc1nc(CC(=O)c2ccc(F)cc2F)[nH]c1CC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
HSD17B10 Q99714 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
ACKR3 P25106 3/20 0.38
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
P2RX7 Q99572 1/20 0.35
KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5850061 0.88 LMNA (0.40) KDM4ELMNAMAPTHSD17B10ALDH1A1
SCHEMBL5850191 0.82 RAB9A (0.42) KDM4ELMNAMAPTHSD17B10ALDH1A1
SCHEMBL5850187 0.79 SMPD3 (0.37) KDM4ELMNAMAPTHSD17B10ALDH1A1
Hydrochloric Acid SCHEMBL5851987 0.77 CES2 (0.41) KDM4ELMNAMAPTHSD17B10ALDH1A1
SCHEMBL5850110 0.72 CES2 (0.39) LMNACES2CES1ACKR3TP53
SCHEMBL5851877 0.71 ACKR3 (0.36) CES2CES1ACKR3L3MBTL1P2RX7
SCHEMBL11015620 0.70 CES2 (0.42) MAPTALDH1A1CES2CES1ACKR3
SCHEMBL29746067 0.70 CES2 (0.61) CES2CES1ACKR3L3MBTL1KCNH2
SCHEMBL196379 0.70 CES2 (0.61) CES2CES1ACKR3L3MBTL1KCNH2
SCHEMBL5850125 0.69 ACKR3 (0.37) LMNAALDH1A1CES2CES1ACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6984646-B2 Imidazopyridinones as p38 map kinase inhibitors BAYER HEALHCARE AG (DE) 2006-01-10 US disclosed
EP-1412353-B1 IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS BAYER HEALTHCARE AG (DE) 2005-03-02 EP disclosed
US-20040220208-A1 Imidazopyridinones as p38 map kinase inhibitors BAYER HEALTHCARE AG (DE) 2004-11-04 US disclosed
EP-1412353-A1 IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS Bayer HealthCare AG (DE) 2004-04-28 EP disclosed
WO-2003008413-A1 IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS BAYER HEALTHCARE AG (DE) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220208-A1 Imidazopyridinones as p38 map kinase inhibitors MAPK1, MAPK3, MAP3K1 KDM4E 1759/4885LMNA 3183/4885MAPT 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.